943975-06-2

Upstream product

• 851883-08-4 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)benzene-1,2-diamine 
• 93-25-4 2-methoxyphenylacetic acid 
• 142682-69-7 ethyl 2-(2-methoxyphenyl)acetimidate hydrochloride 

Downstream Products

• 943972-30-3 C₃₀H₃₄N₈O₂ 
• 943973-85-1 C₃₀H₃₅N₉O 
• 1149613-67-1 C₃₂H₃₇N₉O₂ 
• 943974-01-4 C₃₃H₃₉N₉O₃ 
• 943973-99-7 C₃₃H₄₀N₁₀O₂ 
• 943972-32-5 C₃₄H₄₃N₉O₂ 
• 943974-08-1 C₃₄H₄₁N₉O 
• 1257250-28-4 N-{3-[(dimethylamino)methyl]phenyl}-4-{1-ethyl-3-[2-(2-methoxybenzyl)-1H-benzimidazol-5-yl]-1H-pyrazol-4-yl}pyrimidin-2-amine 

Relevant academic research and scientific papers

PYRIMIDINE INHIBITORS OF KINASE ACTIVITY

Described herein are compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein G1, L1, R2, R3, n, p, Ar1, and Ar2 are defined in the description. Methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-IR are also disclosed.

Development of multitargeted inhibitors of both the insulin-like growth factor receptor (IGF-IR) and members of the epidermal growth factor family of receptor tyrosine kinases

Emerging clinical and pre-clinical data indicate that both insulin-like growth factor receptor (IGF-IR) and members of the epidermal growth factor (EGF) family of receptor tyrosine kinases (RTKs) exhibit significant cross-talk in human cancers. Therefore, a small molecule that successfully inhibits the signaling of both classes of oncogenic kinases might provide an attractive agent for chemotherapeutic use. Herein, we disclose the structure activity relationships that led to the synthesis and biological characterization of 14, a novel small molecule inhibitor of both IGF-IR and members of the epidermal growth factor family of RTKs.